

## Product datasheet for **KN508954**

### **King1 Mouse Gene Knockout Kit (CRISPR)**

#### **Product data:**

Product Type:	Knockout Kits (CRISPR)
Format:	2 gRNA vectors, 1 linear donor
Donor DNA:	EF1a-GFP-P2A-Puro
Symbol:	King1
Locus ID:	16644



[View online »](#)

**Components:**
**KN508954G1**, King1 gRNA vector 1 in pCas-Guide CRISPR vector (GE100002)

**KN508954G2**, King1 gRNA vector 2 in pCas-Guide CRISPR vector (GE100002)

**KN508954D**, Linear donor DNA containing LoxP-EF1a-tGFP-P2A-Puro-LoxP:

The sequence below is cassette sequence only. The linear donor DNA also contains proprietary target sequence.

LoxP-EF1a-tGFP-P2A-Puro-LoxP (2739 bp)

```

ATAACTTCGT ATAATGTATG CTATACGAAG TTATCGTGAG GCTCCGGTGC CCGTCAGTGG GCAGAGCGCA
CATCGCCAC AGTCCCGAG AAGTTGGGG GAGGGTTCGG CAATTGAACC GGTGCCTAGA GAAGGTGGCG
CGGGTAAC TGGAAAGTG ATGTCGTGTA CTGGCTCCG CTTTTCCCG AGGGTGGGG AGAACCGTAT
ATAAGTCAG TAGTCGCCG GAACGTTCT TTTCCGAACG GGTTCGCCG CAGAACACAG GTAAGTGCCG
TGTGTGGTTC CCGCGGGCT GGCCTCTTA CGGGTTATGG CCCTTGCGTG CCTTGAATTA CTTCCACCTG
GCTGCAGTAC GTGATTCTG ATCCCGAGCT TCGGGTTGGA AGTGGGTGG AGAGTTCGAG GCCTTGCGCT
TAAGGAGCCC CTTCGCCTG TGCTTGAGT GAGGCCTGGC CTGGGCGCTG GGGCCCGCG GTGCGAATCT
GGTGGCACCT TCGCGCCTG CTCGCTGCT TCGATAAGT TCTAGCCATT TAAAATTTT GATGACCTGC
TGCAGCGCT TTTTCTGGC AAGATAGTCT TGTAATGCG GGCCAAGATC TGCACACTGG TATTTTCGTT
TTTGGGGCCG CGGGCGGCA CGGGGCCCGT GCGTCCCAGC GCACATGTTC GGCAGGCGG GGCCTGCGAG
CGCGGCCACC GAGAATCGGA CGGGGTAGT CTCAAGCTGG CCGGCCTGCT CTGGTGCCTG GCCTCGCGCC
GCCGTGTATC GCCCGCCCT GGGCGGAAG GCTGGCCCG TCGGCACCAG TTGCGTGAGC GGAAAGATGG
CCGTTCCCG GCCCTGTGC AGGGAGCTCA AAATGGAGGA CGCGCGCTC GGGAGAGCGG GCGGGTGAAGT
CACCCACACA AAGGAAAAGG GCCTTCCGT CCTCAGCCG CGCTTCATGT GACTCCACGG AGTACCGGGC
GCCCTCCAG CACCTCGAT AGTTCTCGAG CTTTGGAGT ACGTGCTCT TAGTTGGGG GGAGGGGTTT
TATGCGATGG AGTTTCCCA CACTGAGTGG GTGAGACTG AAGTTAGGCC AGCTTGGCAG TTGATGTAAT
TCTCCTTGA ATTTGCCCT TTTGAGTTG GATCTTGGT CATTCTCAAG CCTCAGACAG TGGTTCAAAG
TTTTTTCTT CCATTTCAAG TGTCGTGAAT GGAGAGCGAC GAGAGCGGCC TGCCCGCCAT GGAGATCGAG
TGCCGCATCA CCGGCACCCT GAACGGCGTG GAGTTCGAGC TGGTGGGCGG CGGAGAGGGC ACCCCGAGC
AGGGCCGCAT GACCAACAAG ATGAAGAGCA CCAAAGGCGC CCTGACCTTC AGCCCTACC TGCTGAGCCA
CGTGATGGC TACGGCTTCT ACCACTTCG CACCTACCC AGCGGCTACG AGAACCCCTT CCTGCACGCC
ATCAACAACG GCGGCTACAC CAACCCCGC ATCGAGAAGT ACGAGGACGG CGGCGTGCTG CACGTGAGCT
TCAGCTACCG CTACGAGGC GCGCGCTGA TCGGCGACTT CAAGGTGATG GGCACCGGCT TCCCGGAGGA
CAGCGTGATC TTCACCGACA AGATCATCCG CAGCAACGCC ACCGTGGAGC ACCTGCACCC CATGGCGGAT
AACGATCTGG ATGGCAGCTT CACCCGACC TTCAGCCTGC GCGACGGCGG CTACTIONAGC TCCGTGGTGG
ACAGCCACAT GCACTTCAAG AGCGCCATCC ACCCCAGCAT CCTGCAGAAC GGGGGCCCA TGTTCCCTT
CCGCCCGTG GAGGAGGATC ACAGCAACAC CGAGTGGGC ATCGTGGAGT ACCAGCACGC CTTCAAGACC
CCGGATGCAG ATGCCGGTGA AGAAAGAGGA AGCGGAGCTA CTAACCTCAG CCTGCTGAAG CAGGCTGGAG
ACGTGGAGGA GAACCCTGGA CCTATGACCG AGTACAAGC CACGGTGC GCCTGCCACC GCGACGACGT
CCCCAGGGC GTACGCACC TCGCCGCCG GTTCGCCGAC TACCCGCCA CGGCCACAC CGTCGATCCG
GACCGCCACA TCGAGCGGT CACCGAGCTG CAAGAACTCT TCCTCACGG CGTCGGGCTC GACATCGCA
AGGTGTGGT CCGGACGAC GCGCCCGCG TGGCGTCTG GACCACGCG GAGAGCGTCG AAGCGGGGGC
GGTGTTCGC GAGATCGGC CGCGCATGG CGAGTTGAGC GGTTCGGGC TGGCCCGCA GCAACAGATG
GAAGCCCTC TGCGCCGCA CCGGCCAAG GAGCCCGCT GTTCTCTGG CACCCTCGG GTCTCGCCG
ACCACCAGG CAAGGTCTG GGCAGCGCG TCGTGTCCC CGGAGTGGAG GCGGCCGAGC GCGCCGGGT
GCCCGCTT CTGGAGACT CCGCGCCCG CAACCTCCC TTCTACGAG GGCTCGGCT CACCGTCACC
GCCGACGTC AGGTGCCGA AGGACCGCG ACCTGGTGA TGACCCGCA GCCCGGTGCC TGAAACTTGT
TTATTGCAG TTATAATGG TACAAATAA GCAATAGCAT CACAAATTC ACAAATAAG CATTTTTTT
ACTGCATTCT AGTTGTGGT TGTCAAAC CATCAATGA TCTTAATAA TTCGTATAAT GTATGCTATA CGAAGTTAT
    
```



**Disclaimer:** These products are manufactured and supplied by OriGene under license from ERS. The kit is designed based on the best knowledge of CRISPR technology. The system has been functionally validated for knocking-in the cassette downstream the native promoter. The efficiency of the knock-out varies due to the nature of the biology and the complexity of the experimental process.

**RefSeq:** [NM\\_001102411](#), [NM\\_001102412](#), [NM\\_023125](#)

**UniProt ID:** [O08677](#)

**Synonyms:** Kng

**Summary:** (1) Kininogens are inhibitors of thiol proteases; (2) HMW-kininogen plays an important role in blood coagulation by helping to position optimally prekallikrein and factor XI next to factor XII; (3) HMW-kininogen inhibits the thrombin- and plasmin-induced aggregation of thrombocytes; (4) the active peptide bradykinin that is released from HMW-kininogen shows a variety of physiological effects: (4A) influence in smooth muscle contraction, (4B) induction of hypotension, (4C) natriuresis and diuresis, (4D) decrease in blood glucose level, (4E) it is a mediator of inflammation and causes (4E1) increase in vascular permeability, (4E2) stimulation of nociceptors (4E3) release of other mediators of inflammation (e.g. prostaglandins), (4F) it has a cardioprotective effect (directly via bradykinin action, indirectly via endothelium-derived relaxing factor action); (5) LMW-kininogen inhibits the aggregation of thrombocytes; (6) LMW-kininogen is in contrast to HMW-kininogen not involved in blood clotting (By similarity).[UniProtKB/Swiss-Prot Function]

### Product images:

